Bioanalytics
John Gebler, PhD
Director, Strategic Biopharma Business Dev
Phenomenex
Torrance, California
Description: Size exclusion, ion-exchange, and other common separation methods have been fundamental in the analytics of biologic based therapies. Typical biologics required complex and comprehensive analytical methods for discovery, development, and manufacturing. Due to the acceleration and efficiency expectations of the biopharma industry there is a need for improvements in separation and sample prep technologies. In addition, the industry expects a level of performance that are technologies/methods that are robust and reproducible. Many current analytical methods employ old technology with time consuming or labor-intensive methods. The overall pharmaceutical industry drives timelines to first in patient. The COVID pandemic has demonstrated that when pressure tested, the industry can deliver life-saving therapies in much shorter timelines. With the bar now reset, this presentation will discuss requirements and suggestions for what is needed to achieve these efficiencies.